Drugs and patents in ATC class D05

Last updated: June 11, 2026

Market dynamics and patent landscape for ATC Class D05 antipsoriatics (top systemic, biologic, small-molecule, and topical franchises)

ATC D05 antipsoriatics is split between (1) topical anti-inflammatory and keratolytic regimens, (2) systemic small molecules (notably PDE4 inhibition and TYK2/JAK/IL-23 axis agents where applicable), and (3) biologics (IL-17, IL-23, and TNF inhibitors). The patent landscape is driven by long-lived formulation and dosing patents in topicals, method-of-use and biologic sequence and composition-of-matter protection in biologics, and tight exclusivity windows for new IL-23/IL-17 and TYK2/JAK classes. Patent cliffs for older TNF and early biologics are creating steady generic and biosimilar entry pressure, while newer mechanisms have extended estates via multiple “secondary” patents: dosing regimens, device-delivery, biomarkers, and combination therapy claims.

Net effect: market share and pricing are increasingly determined by biosimilar switching dynamics (dermatology formularies, payer step edits, and pharmacy benefit contracting) and by the strength and timing of secondary patents around autoinjectors, loading doses, and fixed-dose combination regimens.

How big is the ATC D05 antipsoriatics market, and what drives demand?

Featured-snippet answer: Demand is driven by plaque psoriasis incidence, biologic uptake versus topical management, payer policies that push step therapy, and biosimilar availability for older biologic blocks.

What product segments dominate ATC D05

Topicals (D05A through D05B and adjacent subclasses): corticosteroids, vitamin D analogs, retinoids, keratolytics, combination products.
Systemics (D05B and non-topical antipsoriatics): biologics and small molecules used for moderate-to-severe disease.
Phototherapy is outside drug ATC D05 but affects utilization.

Market dynamics that affect patent outcomes

Payer switching: biosimilars accelerate after tender cycles and formulary revisions for IL-17/IL-23/TNF classes.
Adherence and delivery IP: autoinjector and prefilled syringe device patents can sustain exclusivity-like commercial moat even after biologic primary protection ends.
Line of therapy: switching earlier in the treatment line improves biosimilar penetration but depends on patent status of induction and maintenance regimens.

What patents protect antipsoriatics in the ATC D05 class?

Featured-snippet answer: The protection stack spans composition-of-matter, formulation and device delivery, method-of-use (indication and dosing), and, for biologics, sequence and glycosylation/variant specifications plus composition and manufacturing method claims.

Topical (D05) IP patterns

Topical psoriasis products usually combine:

Composition and formulation patents: concentration ranges for actives, stability, penetration enhancers, vehicles, and tackifiers for gels/foams.
Therapeutic method patents: dosing frequency, occlusion regimes, body-site-specific dosing.
Device and packaging: child-resistant containers, metered dispensers, and patch formats where used.

Biologics (anti-IL-17, anti-IL-23, anti-TNF) IP patterns

Biologics typically have:

Primary estate: biologic sequence, variants, and post-translational processing.
Secondary estate: specific dose regimens (loading/maintenance), combination regimens, and switching/withdrawal protocols.
Manufacturing and control patents: production cell line/process parameters, analytical characterization (CMC) tied to commercial manufacturing.

Small molecules (systemic) IP patterns

Small molecules are governed by:

Core compound patents (composition-of-matter).
Salt/crystal form and polymorph patents.
Formulation and controlled-release patents.
Method-of-use claims for dose and titration schedules.

Which companies hold the strongest patent estates in ATC D05 antipsoriatics?

Featured-snippet answer: IP strength concentrates among originators with IL-17 and IL-23 biologics, followed by PDE4 and TYK2/JAK originators where present for psoriasis indications, and by incumbents with entrenched topical combination and delivery technologies.

Originator blocs that typically dominate

IL-17 axis: incumbents with high market share and dense secondary estates around dosing and delivery devices.
IL-23 axis: newer originators with multi-patent dosing, combination, and patient selection claims.
TNF inhibitors: older estates with recurring generic/biosimilar pressure post-expiration.
Topicals: incumbents with combination products and device packaging.

When do key antipsoriatics patents expire and lose exclusivity?

Featured-snippet answer: Exclusivity loss is staggered: biologic primary patents and related biologic-specific method claims expire first, then dosing regimen and delivery device patents provide later “last mile” barriers.

Typical timing pattern for antipsoriatics

Year 0-7: primary compound or biologic sequence/variant estate dominates.
Year 5-15: secondary patents (dose regimens, combinations, delivery) extend commercial exclusivity.
Year 10-20: patent cliffs accelerate for older TNF and legacy topical franchises, feeding biosimilar and generic entries.

Patent cliff dynamics by modality

Biologics: cliff is rarely a single date due to multiple families tied to dosing, manufacturing, and device.
Topicals: even when actives are old, formulation/device patents can block direct “drop-in” generics.
Small molecules: salt/polymorph and extended-release formulations can extend practical exclusivity even after core compound expiry.

How many patents cover major antipsoriatics drugs, and what are the most common claim types?

Featured-snippet answer: Estates for leading psoriasis biologics commonly include multiple families with dozens of active patents globally; the most common claim types are dosing/method-of-use, formulation/device, and CMC/manufacturing.

Claim categories that matter for entry

Method-of-use: induction and maintenance dosing schedules.
Composition/formulation: vehicle, concentration ranges, and penetration characteristics for topicals.
Device-delivery: autoinjector or prefilled syringe configurations and dosing accuracy.
Biologic CMC: manufacturing process parameters and characterization linked to functional similarity.
Combination therapy: co-administration with topical agents or systemic background therapy.

What patent litigation affects antipsoriatics, including biosimilar and generic challenges?

Featured-snippet answer: Litigation clusters around Paragraph IV-type generic challenges for small molecules and FDA-type biosimilar patent listings for biologics, with settlement agreements often containing market-entry timing restrictions tied to patent expiry.

Litigation channels by modality

Small molecules (generics): Orange Book listed patents determine eligibility for ANDA challenges and settlement exposure.
Biologics (biosimilars): patent lists and the biosimilar litigation framework determine stay/launch dates.
Topicals (generics): courts focus on formulation equivalence, vehicle penetration claims, and method-of-use infringement.

Common settlement structures

Launch-date covenants aligned to patent expiry.
No-advertising/no-sublicense restrictions until defined milestones.
Geographic carve-outs for distribution channels or secondary markets.

What is the Orange Book status of top antipsoriatics, and which patents are typically listed?

Featured-snippet answer: For small molecules, Orange Book lists composition-of-matter, method-of-use, and formulation/device patents. For biologics, the Biologics License Application patent listing framework governs, not the Orange Book.

Orange Book patent listing patterns

Drug substance patents (compound and salts/polymorphs)
Drug product/formulation patents (dosage form, release profile)
Method-of-use (indication and dosing)
Combination products (co-formulated actives)

What “listed patents” often control

For entry strategy, litigation risk is highest where method-of-use dosing claims are narrow but clearly practiced in the label or in the applicant’s proposed label regimen.

How do biosimilar risks differ across IL-17, IL-23, and TNF antipsoriatics?

Featured-snippet answer: IL-17 and IL-23 biosimilars face dense secondary dosing/device and CMC-related patent estates; TNF biosimilars typically face older estates with more frequent early entrants.

Risk drivers

Secondary patents: dosing and delivery can block “label-accurate” biosimilar launches.
CMC claim coverage: manufacturing process constraints can drive litigation even when primary sequence protection ends.
Formulary and switch timing: risk is compounded by payer behavior and contracting, which can accelerate or delay uptake.

Market impact mechanism

Faster biosimilar adoption increases erosion of originator revenue and compresses the value of late-arriving secondary patents, but device/dosing patents can still delay competitive substitution.

Which formulations are protected by antipsoriatics patents, and how does that affect generic and biosimilar entry?

Featured-snippet answer: For topicals and some systemics, formulation patents around vehicles, penetration, stability, and device dosing systems are common blocking points for generic entry.

Topical formulation protection hotspots

Vehicle systems for creams, ointments, gels, foams
Penetration enhancers and occlusive agents
Stability and shelf-life parameters
Concentration ranges and layered combinations

Systemic formulation protection hotspots

Fixed-dose combinations (where approved)
Controlled-release and specific excipient sets
Prefilled syringe/autoinjector compatibility with dosing accuracy claims

How does ATC D05 compare across major competitors: originator vs biosimilar vs generic?

Featured-snippet answer: The competitive gap narrows as biosimilar penetration rises, but originators retain leverage through dosing regimens, delivery devices, and payer contract structures.

Originator advantage profile

Stronger label-specific dosing and induction protocols
Device ecosystem and clinician familiarity
Patent density across secondary families

Biosimilar advantage profile

Lower acquisition cost once entry is authorized
Fast formulary adoption when litigation delays end
Ability to leverage payer switching

Generic advantage profile (small molecules and topicals)

Price compression when Orange Book barriers are cleared
Entry speed depends on patent listings and method-of-use claim status

What generic entry risks exist for ATC D05 small-molecule antipsoriatics?

Featured-snippet answer: Entry risk is highest when Orange Book lists method-of-use and formulation patents with label-consistent dosing that the generic must replicate.

Risk ladder

Method-of-use patent aligned to label dosing: highest infringement likelihood.
Formulation/polymorph patents: block “bioequivalent in practice” formulations.
Salt/crystal form patents: restrict formulation route.
Device patents (if applicable): can block launch if delivery system infringes.

How does geographic coverage affect antipsoriatics exclusivity and litigation outcomes?

Featured-snippet answer: Patent enforcement and regulatory exclusivity differ by jurisdiction, so launch timing depends on national patent status, not only regulatory approval dates.

Jurisdictional effects

US: Orange Book/BPCIA patent listings drive biosimilar/generic launch litigation timing.
EU: SPC/second-use and national enforcement determine competitive timelines.
UK and key markets: parallel patent families and enforcement venues affect settlement outcomes.

Practical result

Companies often plan launches around “earliest enforceable” expiry in the largest payer markets, then sequence subsequent countries.

Timeline: how antipsoriatics exclusivity typically cascades from primary to secondary patents

Featured-snippet answer: Primary protection expires first, but device and dosing secondary patents can maintain market barriers across an additional multi-year window.

Representative cascades

Primary compound/sequence expiry: start of erosion risk for originator revenue.
Secondary dosing and method claims expiry: affects label-specific launch ability.
Formulation and device expiry: affects device parity and friction costs for payer switching.
CMC-related claims and enforcement: can delay manufacturing authorization even after clinical label approval.

Key Takeaways

ATC D05 antipsoriatics market dynamics are dominated by biosimilar switching and by patent density across secondary families, especially dosing regimens and device delivery for biologics and formulation/vehicle patents for topicals.
Exclusivity and entry timelines are rarely driven by a single “primary” expiry date; they cascade across method-of-use, formulation, and device patents.
Litigation risk for entrants concentrates on method-of-use and delivery-related claims that are consistent with proposed label and real-world dosing practices.
Geographic launch sequencing depends on enforceable patent expiry dates and enforcement venue outcomes, not just regulatory approvals.

FAQs

What patent types most commonly delay biosimilar launches in antipsoriatics?
How do payer formulary step edits interact with patent expiry for IL-23 and IL-17 drugs?
Do topical antipsoriatics generics face more vehicle/formulation barriers than actives-related barriers?
What settlement terms are most common in antipsoriatics biosimilar or generic patent disputes?
How does device-delivery IP (autoinjector/prefilled syringe) change competitive substitution after patent expiry?

References (APA)

FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
FDA. (n.d.). Purple Book: Lists of Licensed Biological Products. U.S. Food and Drug Administration.
FDA. (n.d.). Biosimilar Product Information. U.S. Food and Drug Administration.
U.S. Congress. (2020). Biologics Price Competition and Innovation Act (BPCIA). (As amended).

Subclasses in ATC: D05 - ANTIPSORIATICS